Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from TMS Co., Ltd. ( (JP:4891) ) is now available.
TMS Co., Ltd. announced a change in its fiscal year end to align with global standards, moving from February 28 to December 31. This change aims to enhance business efficiency and improve information disclosure to investors. The transitional fiscal year will be ten months long, and the company plans to disclose estimated operating expenses in April 2025. The amendment to the Articles of Incorporation related to this change will be discussed at the shareholder meeting in May 2025.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for serious diseases with high unmet medical needs. Their pipeline includes small molecule compounds called SMTPs, with their lead program TMS-007 showing promise in treating acute ischemic stroke. The company also explores treatments for hypertension, kidney injury, and spinal cord injury, leveraging partnerships with academic institutions in Japan.
YTD Price Performance: -4.13%
Average Trading Volume: 1,735,106
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen8.43B
See more insights into 4891 stock on TipRanks’ Stock Analysis page.